Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial.

Egle, A; Melchardt, T; Obrtlíková, P; Smolej, L; Kozák, T; Steurer, M; Andel, J; Burgstaller, S; Mikušková, E; Gercheva, L; Nösslinger, T; Papajík, T; Ladická, M; Girschikofsky, M; Hrubiško, M; Jäger, U; Voskova, D; Pecherstorfer, M; Králiková, E; Burcoveanu, C; Spasov, E; Petzer, A; Mihaylov, G; Raynov, J; Oexle, H; Zabernigg, A; Flochová, E; Palášthy, S; Stehlíková, O; Doubek, M; Altenhofer, P; Weiss, L; Magnes, T; Pleyer, L; Klingler, A; Mayer, J; Greil, R.

Cancer Med. 2019 Apr;8(4):1401-1405. doi: 10.1002/cam4.1980. Epub 2019 Mar 19.

https://pubmed.ncbi.nlm.nih.gov/30888118/